Search Results

There are 2457 results for: content related to: Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial

  1. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

    Movement Disorders

    Volume 16, Issue 5, September 2001, Pages: 858–866, William Koller, Andrew Lees, Miroslava Doder, Mariese Hely and the Tolcapone/Pergolide Study Group

    Article first published online : 20 SEP 2001, DOI: 10.1002/mds.1175

  2. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 18 OCT 2004, DOI: 10.1002/14651858.CD004554.pub2

  3. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Drug Development Research

    Volume 42, Issue 1, September 1997, Pages: 1–25, Jasper Dingemanse

    Article first published online : 6 DEC 1998, DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I

  4. Tolcapone, a Selective Catechol-O-Methyltransferase Inhibitor for Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 19, Issue 1, January-February 1999, Pages: 6–20, David R. P. Guay

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.19.1.6.30516

  5. Catechol-O-Methyltransferase (COMT) Inhibitors in Parkinson's Disease

    Journal of the American Geriatrics Society

    Volume 48, Issue 6, June 2000, Pages: 692–698, Cheryl Waters

    Article first published online : 27 APR 2015, DOI: 10.1111/j.1532-5415.2000.tb04732.x

  6. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone

    Clinical Pharmacology & Therapeutics

    Volume 67, Issue 6, June 2000, Pages: 610–620, Karin Jorga, Ludger Banken, Bärbel Fotteler, Paul Snell and Jean-Louis Steimer

    Article first published online : 15 JUN 2000, DOI: 10.1067/mcp.2000.106795

  7. You have free access to this content
    COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

    British Journal of Clinical Pharmacology

    Volume 48, Issue 3, September 1999, Pages: 449–452, Karin M. Jorga and David J. Nicholl

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00027.x

  8. You have free access to this content
    Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase

    British Journal of Clinical Pharmacology

    Volume 48, Issue 4, October 1999, Pages: 513–520, Karin Jorga, Bärbel Fotteler, Peter Heizmann and Rodolfo Gasser

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00036.x

  9. You have free access to this content
    Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

    CNS Neuroscience & Therapeutics

    Volume 14, Issue 1, Spring 2008, Pages: 83–93, Andrew J. Lees

    Article first published online : 14 MAR 2008, DOI: 10.1111/j.1527-3458.2007.00035.x

  10. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

    Movement Disorders

    Volume 13, Issue 4, July 1998, Pages: 643–647, Robert A. Hauser, Eric Molho, Heidi Shale, Simon Pedder and Ernest E. Dorflinger

    Article first published online : 4 NOV 2004, DOI: 10.1002/mds.870130406

  11. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

    Clinical Pharmacology & Therapeutics

    Volume 62, Issue 3, September 1997, Pages: 300–310, Karin M. Jorga, Grzegorz Se̹dek, Bärbel Fotteler, Gerhard Zürcher, Thorkild Nielsen and John W. Aitken

    Article first published online : 22 SEP 1997, DOI: 10.1016/S0009-9236(97)90033-3

  12. Interventions to Achieve Tonic Exposure to Levodopa: Delaying or Preventing the Onset of Motor Complications

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 19, Issue 11P2, November 1999, Pages: 169S–179S, Mark S. Luer

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.19.17.169S.30886

  13. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

    Clinical Pharmacology & Therapeutics

    Volume 63, Issue 6, June 1998, Pages: 646–654, Karin M. Jorga, Jan Martin Kroodsma, Baerbel Fotteler, Peter Heizmann, Joseph Meyer, Mareike C. Rasch and Jan van Hattum

    Article first published online : 19 JUN 1998, DOI: 10.1016/S0009-9236(98)90088-1

  14. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 18 OCT 2004, DOI: 10.1002/14651858.CD004553.pub2

  15. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat

    British Journal of Pharmacology

    Volume 172, Issue 7, April 2015, Pages: 1739–1752, M J Bonifácio, L Torrão, A I Loureiro, P N Palma, L C Wright and P Soares-da-Silva

    Article first published online : 20 JAN 2015, DOI: 10.1111/bph.13020

  16. You have free access to this content
    Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

    British Journal of Clinical Pharmacology

    Volume 40, Issue 3, Sep 1995, Pages: 253–262, J. Dingemanse, K. Jorga, G. Zurcher, M. Schmitt, G. Sedek, M. Da Prada and P. Van Brummelen

    Article first published online : 4 JUL 2012, DOI: 10.1111/j.1365-2125.1995.tb05781.x

  17. COMT inhibitors

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S45–S51,

    Article first published online : 29 JUL 2002, DOI: 10.1002/mds.5560

  18. Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study

    Movement Disorders

    Volume 12, Issue 6, November 1997, Pages: 928–934, Dr. Erik Dupont, Jean-Marc Burgunder, Leslie J. Findley, Jan-Edvin Olsson and Ernest Dorflinger

    Article first published online : 4 NOV 2004, DOI: 10.1002/mds.870120615

  19. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

    Synapse

    Volume 43, Issue 3, 1 March 2002, Pages: 201–207, Roberto Ceravolo, Paola Piccini, Dale L. Bailey, Karin M. Jorga, Helen Bryson and David J. Brooks

    Article first published online : 14 DEC 2001, DOI: 10.1002/syn.10034

  20. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

    Clinical Pharmacology & Therapeutics

    Volume 57, Issue 5, May 1995, Pages: 508–517, Jasper Dingemanse, Karin M. Jorga, Monique Schmitt, Ronald Gieschke, Bärbel Fotteler, Gerhard Zürcher, MoséDa Prada and Peter van Brummelen

    Article first published online : 17 MAY 1995, DOI: 10.1016/0009-9236(95)90035-7